Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009 by Zhu, Hao et al.
Decreasing Excess Mortality of HIV-infected Patients Initiating
Antiretroviral Therapy: Comparison with Mortality in General
Population in China, 2003 – 2009
H. ZHU1,3, S. NAPRAVNIK1,2, J.J. ERON1,2, S.R. COLE1, Y. MA3, D.A. WOHL2, Z. DOU3, Y.
ZHANG3, Z. LIU3, D. ZHAO3, L. YU3, X. LIU3, M.S. COHEN1,2,*, and F. ZHANG3,4,*
1Department of Epidemiology, Gillings School of Global Public Health, University of North
Carolina at Chapel Hill, NC, USA
2Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill,
NC, USA
3National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and
Prevention, Beijing, China
4Beijing Ditan Hospital Capital Medical University, Beijing, China
Abstract
Objective—To evaluate excess mortality across calendar time comparing HIV-infected patients
receiving cART with the general Chinese population.
Methods—Patients receiving free cART through the National Free Antiretroviral Therapy
Program (NFATP) between 1 January 2003 and 31 December 2009 were included. Observed
mortality rates, excess mortality rates and standardized mortality ratios were calculated by
calendar periods. Factors associated with excess mortality across calendar time were evaluated in
multivariable Poisson regression models.
Results—Among 64,836 HIV-infected patients the observed and excess mortality rates in
2003/2004 were 9.5 deaths/100 person-years (95% confidence interval [95% CI]: 8.8, 10.2) and
9.1 (8.5, 9.8); in 2008/2009 these decreased to 5.6 (5.4, 5.8) and 5.2 (5.0, 5.4) respectively. The
adjusted excess hazard ratio (eHR) for 2003/2004 in comparison to 2008/2009 was 1.27 (95% CI:
1.11, 1.45). Patients initiating cART at CD4 cell counts <50 cells/μL in comparison to ≥350 cells/
μL had an adjusted eHR of 9.92 (95% CI: 8.59, 11.44). Patients starting cART at older ages also
had greater excess mortality with an eHR of 1.63 (95% CI: 1.47, 1.82) comparing ages ≥ 45 to 18–
29. Standardized mortality ratio results were consistent with those for excess mortality.
Conclusion—Substantial decreases in excess mortality were observed from 2003 to 2009 in
China among HIV-infected patients receiving free cART. However, mortality among HIV-
infected patients remained higher than the general Chinese population. As more efficacious first
and second line cART regimens become increasingly available to Chinese HIV-infected patients,
further reductions in overall and excess mortality are likely.
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Introduction
Combination antiretroviral therapy (cART) provision enables human immunodeficiency
virus (HIV)-infected patients to suppress HIV replication 1–3, leading to substantially lower
morbidity and mortality in both resource rich and poor areas of the world 4, 5. A number of
prior studies have observed notable reductions in mortality across calendar time with
increasing uptake of more efficacious cART 6–8. However, mortality among HIV-infected
patients remains higher in resource poor areas even where cART is available 9.
Reductions in mortality from HIV-infection have also been narrowing the gap in life
expectancy comparing HIV-infected patients to the general population 10–13. Among some
HIV-infected patients life expectancy may approach that observed in the general
population 14, 15. For example, among West and South African patients participating in the
International epidemiological Databases to Evaluate AIDS project who initiated cART at
higher CD4 counts life expectancy estimates approach those of HIV-uninfected
individuals 16. Mortality and life expectancy contrasts comparing HIV-infected patients
receiving cART to the general population assess the effectiveness of provided HIV therapy
at a population level. These types of analyses also provide data for policy makers for
assessing future needs of HIV-infected patients and in planning allocation of health care and
other resources.
The Joint United Nations Programme on HIV/AIDS estimated that as of 2009, 740,000
(range 540,000–1,000,000) adults and children were living with HIV in China 17. Since
2002, HIV-infected patients in China have had access to free cART through the National
Free Antiretroviral Treatment Program (NFATP) 18, and as of 2009 over 80,000 patients
received cART through this program 19. As elsewhere around the world, HIV-infected
patients receiving cART experience notable reductions in morbidity and mortality in
China 19–21. Although NFATP only launched the national free cART program in the last
decade, notable decreases in mortality across calendar time have already been reported 22.
However, this prior work has concentrated on internal comparisons of mortality among
HIV-infected patients over time, and therefore cannot distinguish mortality time trends
among HIV infected patients from temporal trends in the Chinese population. In the present
study we compare mortality estimates between HIV-infected patients receiving cART
through NFATP with the general Chinese population from 2003 and 2009. We estimated
both excess mortality and standardized mortality ratios over calendar time and evaluated risk
factors for excess mortality.
Methods
Study population
Patients receiving free cART through NFATP between 1 January 2003 and 31 December
2009 were included 18, 23, 24. Patients were cART eligible if they had a CD4 count below
200 cells/μL (increased to 350 cells/μL in 2008), a total lymphocyte counts <1200 cells/μL
or a World Health Organization stage III or IV clinical condition 25. Standardized paper-
based case report forms were completed by local health workers. Information included
demographic data, HIV exposure route, clinical symptoms and signs, cART administered
and laboratory test results. Subsequent follow up visits occurred at 2, 4, 8 and 12 weeks
following cART initiation, and then every 3 months thereafter. We excluded patients who
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did not have information on area of residence (n=10,669) and who did not have any follow-
up visit information before 15 December 2009 (n=714). This study was approved by the
Institutional Review Board at the University of North Carolina at Chapel Hill and the
National Center for AIDS/STD Control and Prevention at China Center for Disease Control
and Prevention.
Measurements
Factors measured at the first visit included age, sex, likely HIV exposure route, initial cART
regimen, CD4 cell count, type of health care setting and area of residence (rural versus
urban). Antiretroviral therapy regimens were categorized as: neviripine (NVP) with
lamivudine (3TC) and either zidovudine (AZT) or stavudine (d4T); efavirenz (EFV) with
3TC and either AZT or D4T; NVP and didanosine (DDI) and either AZT or D4T; and all
other regimens. HIV exposure route included infection through blood transfusion/former
plasma donation, sexual transmission and injection drug use (IDU). Information on death,
including reason and date of death, was available through the NFATP treatment withdrawal
forms. These forms were also completed by local health workers and sent to central NFATP
offices by DataFax (Clinical DataFax Systems, Hamilton, Ontario, Canada). Forms were
completed on all patients known to have died at the local level through passive surveillance.
Mortality data for the general Chinese population was obtained from China Health Statistic
Year Book 2004 to 2010 26. These national death statistics are based on a passive
surveillance system, i.e. the Ministry of Health-vital registration system, to report death
cases to a central national repository 27.
Statistical analysis
Person-time was calculated from the date when patients initiated cART to the date of death
or date of censoring. Patients were censored either at the date of withdrawal from NFATP or
31 December 2009, whichever occurred first. The reason for withdrawal included loss to
follow up, treatment interruption or transferring to another health care facility. Loss to
follow-up was defined as missing more than 3 visits and we used the latest date seen in
clinic as the date of withdrawal.
Observed mortality rates were calculated as number of deaths divided by person-years at
risk and corresponding 95% confidence intervals (95% CIs) were calculated as:28
Where R is observed mortality rates and n is the number of deaths. Expected number of
deaths was estimated by applying the probability of death in the general Chinese population
to the study population in each calendar year. Patients were matched to the general
population on age (by 5 year age group), sex, area of residence (urban versus rural) and
calendar year.
Excess mortality rates were calculated as the difference between observed deaths in the
study population and that expected based on estimates from the general population.
Standardized mortality ratios (SMR) were calculated as the ratio of the observed number of
deaths in the study population to that expected from estimates based on the general
population. As measures of precision we calculated 95% CIs for both excess mortality rates
and standardized mortality ratios28. Excess mortality rates and standardized mortality ratios
were estimated within strata defined by calendar year interval (2003–2004, 2005–2007 and
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2008–2009). This categorization was chosen to: minimize heterogeneity within groups;
correspond with major therapeutic changes across calendar time; and preserve adequate
sample sizes within strata. Further stratification of estimates was done according to patients’
age, sex, HIV exposure route, CD4 count at cART initiation, area of residence, type of
health care settings and type of first cART regimen received.
We further evaluated changes in excess mortality across calendar time in multivariable
Poisson regression models 29. In this relative survival model, the observed number of deaths
in each patient stratum was modeled with a Poisson process and we used the expected
number of deaths in each stratum as an offset. Time was categorized into one year
increments from cART initiation, assuming a piecewise constant hazard within each year
after starting cART. Excess hazard ratios (eHRs) and associated 95% CIs were obtained as
the antilog of the coefficient from this relative survival model. We examined changes in
relative survival across calendar time adjusting for age, sex, HIV-exposure category, CD4
count, initial cART regimen, type of health care setting and area of residence. In this case
the interpretation of eHR comparing calendar years is similar to other survival models, such
that the index group of patients experiences an instantaneous risk of death “eHR” times the
risk among patients in the reference group, accounting for expected background mortality
and the other patient characteristics included in the model. In all analyses hypothesis testing
was 2-sided and an alpha of 0.05 was used to indicate a statistically significant difference.
All analyses were done using SAS version 9.2 (SAS Institute, Cary NC, USA).
Results
Overall 64,836 HIV-infected patients with known area of residence initiated cART in the
Chinese NFATP between 2003 and 2009 and were included in this analysis. The proportion
of patients receiving treatment increased up over time and almost half of patients initiated
cART during 2008 and 2009 (47%) (Table 1). The median age at cART initiation was 38
years [interquartile range (IQR): 33 – 46], 40% of patients were women, and 70% lived in
rural areas. In more recent years patients appeared younger at cART initiation, were more
likely to be men, and more likely to live in urban areas. In 2003 and 2004 95% of patients
were infected through blood transfusion/former plasma donation, and this decreased to 18%
by 2008 and 2009.
The median CD4 count at cART initiation decreased across time from 223 cells/mL in
2003/2004 to 141 cells/mL in 2008/2009. Although NVP remained the most common
anchor agent provided, the use of 3TC replaced DDI in 2005/2006. Specifically in
2003/2004 patients predominantly received NVP and DDI with either AZT or D4T (89%),
in comparison in 2008/2009 the most common first cART regimen was NVP and 3TC with
either AZT or D4T (73%).
Patients were followed on average for a median of 1.5 years (IQR: 0.5 – 3.4), contributing a
total of 135,509 person-years of follow-up (Table 2). Overall 13% of patients were known to
have died (n=8,577), with an observed mortality rate of 6.3 deaths/100 person-years (95%
CI: 6.2 – 6.4). The crude observed mortality rate decreased across calendar time from 9.5 to
5.6 deaths/100 person-years from 2003/2004 to 2008/2009.
The overall excess mortality rate was 6.0 deaths/100 person-years (95% CI: 5.9, 6.1). Excess
mortality fell from 9.1 deaths/100 person-years (95% CI: 8.5, 9.8) in 2003/2004 to 5.2
deaths/100 person-years (95% CI: 5.0, 5.4) in 2008/2009 (Table 2). The reductions in excess
mortality rates across calendar time were evident within all strata of patient characteristics,
including age, sex, CD4 count at cART initiation and type of initial cART (Table 3). In
unadjusted analyses excess mortality rates were higher among older patients in each stratum
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of calendar years, although younger patients in 2003/2004 also had high excess mortality.
After adjustment for other patient characteristics, including age, sex, HIV exposure route,
CD4 count, number of baseline symptoms, initial cART regimen, area of residence, and
health care setting, the adjusted excess mortality rates were higher in older patients across all
calendar periods (data not shown here). The most dramatic reductions in unadjusted excess
mortality rates across calendar time occurred among patients with low CD4 counts at cART
initiation and comparable results were obtained in all strata of CD4 in the adjusted analyses
(data not shown here).
The overall SMR was 20.1 (95% CI: 19.7, 20.5). The SMR decreased from 30.8 (95% CI:
28.6, 33.1) to 17.0 (95% CI: 16.5, 17.6) from 2003/2004 to 2008/2009 (Table 2). In general
SMR results stratified by patient characteristic were comparable to results observed for
excess mortality rates (Table 4). As observed with excess mortality rates, the reduction in
SMR across calendar time was most dramatic among patients initiating cART at low CD4
counts. Among patients with CD4 counts below 50 cells/μL the SMR declined from 103.6
(95% CI: 86.2, 124.5) to 32.2 (95% CI: 30.5, 34.0) from 2003/2004 to 2008/2009.
The adjusted excess mortality rate decreased from 2003/2004 to 2008/2009, with an eHR of
1.27 (95% CI: 1.11, 1.45), indicating the risk of death was nearly 30% higher in 2003/2004
than 2007/2008, adjusting for background mortality and other patient characteristics
including age, sex, HIV exposure route, area of residence, health care setting, CD4 count,
number of baseline symptoms, and initial cART regimen (Table 5). Patients who were older
at cART initiation were at a greater risk of dying with an eHR of 1.63 (95% CI: 1.47, 1.82)
comparing patients more than 45 years of age to those 18–29. Men, patients living in rural
areas, and those exposed to HIV through IDU were also at higher risk of death. Patients who
received care at larger and centralized medical care facilities appeared to be at lower risk
than those who received care at smaller local centers. Excess mortality decreased with
increasing CD4 counts at cART initiation, with patients who started cART with CD4 counts
less than 50 cells/μL at almost 10 times the risk of death compared to patients with CD4
counts greater than 350 cells/μL (eHR=9.92; 95% CI, 8.59 – 11.44).
Discussion
In this study including over 64,000 HIV-infected patients initiating cART in China, we
found both observed and excess mortality rates decreased more than 30% from 2003 to
2009. Mortality ratios standardized to the general Chinese population also decreased by over
30% from 2003 to 2009. The decreases in excess mortality rates and SMRs across calendar
time were relatively consistently observed within all patient demographic and clinical
characteristics, and after adjusting for a number of factors including age, CD4 count and
cART regimen at therapy initiation, excess mortality decreased by over 20% from
2003/2004 to 2008/2009. These findings are consistent with prior studies which have
reported reductions in observed and expected mortality rates and SMRs across calendar time
among patients initiating cART in both resource rich and poor areas of the
world 15, 16, 30–32.
The observed mortality rate in this study population (6 deaths/100 person-years) was higher
in comparison to results from resource wealthy areas of the world (1 death/100 person-
years) 31, but lower than that observed in Sub-Saharan Africa (8 deaths/100 person-
years) 16. The overall excess mortality we observed was similar to estimates from Sub-
Saharan Africa (6 vs. 7 deaths/100 person-years, respectively), as were the SMRs (20 and
19, respectively) 16, but higher than reported in Europe and North America (excess mortality
rate = 2 deaths/100 person-years 30 and SMR= 3 31)
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Notwithstanding the substantial decreases in mortality rates across calendar time, HIV-
infected patients in this study population consistently had greater excess mortality in
comparison to the general Chinese population. However there were notable differences in
excess mortality rates among groups of patients defined by demographic and clinical
characteristics. Among some groups of patient’s mortality was less than 10 times the general
population whereas among other groups this rose to over 100 times. The greatest differences
in mortality were observed within CD4 count and age strata. The lowest excess mortality
rates were among patients initiating cART at CD4 counts greater than 350 cells/μL. This
group of patients had less than 10 times the mortality of the general population in all
calendar years. In comparison the highest excess mortality rates were observed among
patients initiating cART with CD4 counts less than 50 cells/μL. This group of patients had
over 30 times the mortality of the general population even in the most recent calendar years.
In adjusted analyses patients starting cART with CD4 counts less than 50 cells/μL had
nearly a 10-fold higher excess mortality compared to patients initiating cART at CD4 counts
greater than 350 cells/μL. These findings have been consistently reported from all areas of
the world 12, 16 and underscore recent recommendations that cART be initiated at higher
CD4 counts to optimize overall survival 33–35 and that additional efforts are needed for
earlier HIV diagnosis and treatment initiation among many HIV-infected patients 36.
Overall excess mortality rates increased with increasing age. In multivariable analyses
adjusting for CD4 count and other patient characteristics patients at least 45 years of age had
over 1.6 times excess mortality in comparison to patients 18–29 years of age. Other
independent factors associated with excess mortality in multivariable analyses included
being a male, patients infected through IDU in comparison to sexual transmission, patients
residing in rural versus urban areas, and patients receiving HIV care at local health care
centers in comparison to larger centralized hospital settings. Prior studies have also reported
older age, male sex, and IDU as risk factors for excess mortality 9, 30, 32.
It is possible that the HIV-infected patients in this study population were different from the
general population in other characteristics that we were not able to account for (i.e., age, sex,
area of residence and calendar year) 13. In other words, HIV-infected patients in China may
be at greater risk of death than the general population for reasons other than HIV, such as a
higher prevalence of other comorbidities (e.g., Hepatitis B or C infection). Death
ascertainment relied on reports to HIV care providers, rather than links with centralized
death registries, therefore we may be underestimating the true mortality rates. Mortality
rates of the general Chinese population were based on a passive surveillance system, the
Ministry of Health-vital registration system, which may not capture all deaths in each
province, with some variation by province. We were also unable to account for duration of
HIV-infection, or virologic or immunologic response to cART due to insufficient data.
Observed mortality rates, excess rates and standardized mortality ratios would likely be
lower among patients with better response to cART.
In summary, among HIV-infected patients receiving cART through the Chinese NFATP we
have observed substantial decreases in excess mortality in comparison to the general
Chinese population from 2003 to 2009. Further reductions will likely be achieved as NFATP
is able to provide more efficacious first and second line cART regimens. Our results indicate
that further reductions in mortality will follow if patients are identified earlier after HIV-
infection and are successfully linked with HIV care.
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Table 5
Adjusted excess hazard ratios among 64,836 HIV-infected patients initiating combination antiretroviral
therapy, the China National Free Antiretroviral Treatment Program 2003 – 2009†
eHR (95% CI)
Calendar period of follow up
 2003–2004 1.27 (1.11 – 1.45)
 2005–2007 1.16 (1.09 – 1.23)
 2008–2009 1.00
Age (years)
 ≥45 1.63 (1.47 – 1.82)
 30–44 1.27 (1.15 – 1.40)
 18–29 1.00
Gender
 Men 1.37 (1.29 – 1.45)
 Women 1.00
HIV exposure
 Blood transfusion/former plasma donation 0.98 (0.89 – 1.08)
 Intravenous drug use 1.72 (1.57 – 1.88)
 Sexual transmission 1.00
Area of residence
 Rural 1.17 (1.08 – 1.26)
 Urban 1.00
Health care setting
 General hospital 0.85 (0.76 – 0.95)
 Infectious diseases hospital 0.34 (0.30 – 0.40)
 Centers for diseases control clinic 0.89 (0.81 – 0.97)
 Health care under township level/prison hospital 1.00
CD4 count (cells/μL)
 0–49 9.92 (8.59 – 11.44)
 50–199 4.08 (3.55 – 4.70)
 200–349 1.82 (1.56 – 2.11)
 ≥350 1.00
Number of baseline symptom
 ≥4 2.10 (1.91 – 2.31)
 2–3 1.65 (1.49 – 1.82)
 1 1.35 (1.19 – 1.52)
 0 1.00
Initiation regimen‡
 NVP+3TC+AZT 1.11 (0.94 – 1.31)
 NVP+3TC+D4T 1.09 (0.93 – 1.27)
 NVP+DDI+AZT 1.37 (1.17 – 1.62)
 NVP+DDI+D4T 0.97 (0.80 – 1.17)
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eHR (95% CI)
 Other regimens 1.24 (1.00 – 1.54)
 EFV+3TC+D4T 1.20 (1.00 – 1.43)
 EFV+3TC+AZT 1.00
†
Estimates from one model including all characteristics listed in table
‡
NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz.
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